Current treatment of atypical hemolytic uremic syndrome

Tremendous advances have been made in understanding the pathogenesis of atypical Hemolytic Uremic Syndrome (aHUS), an extremely rare disease. Insights into the molecular biology of aHUS resulted in rapid advances in treatment with eculizumab (Soliris(®), Alexion Pharmaceuticals Inc.). Historically,...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Kaplan, Bernard S., Ruebner, Rebecca L., Spinale, Joann M., Copelovitch, Lawrence
Natura: Artigo
Lingua:Inglês
Pubblicazione: International Research and Cooperation Association for Bio & Socio-Sciences Advancement 2014
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4204535/
https://ncbi.nlm.nih.gov/pubmed/25343125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5582/irdr.2014.01001
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi